17,261 trials
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Participants With Overall Response — 7; 5 Participants
Multiple Sclerosis
Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Overall Response — 4; 4 Participants
Surgical Site Infection
Primary: Number of Patients With a Surgical Site Infection — 10; 13 Participants
Prostate Cancer
Primary: The Number of Participants With Improvement, Disease Progression or Stable Disease — 6; 4; 13 Participants
Pain
Primary: Procedural Distress, OSBD-R — 6.4; 7 Units on a scale
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma
Primary: Progression — 1 Participants
Leukemia, Myelogenous, Chronic
Primary: Participants With Complete Molecular Response (Molecular CR) — 23 Participants
Hepatitis C, Chronic
Primary: Number of Participants With Adverse Events (AEs) — 15; 9 participants
HIV Infection · Gastrointestinal Symptoms
Primary: Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues
Tibial Meniscus Injuries · Osteoarthritis, Knee
Primary: Change in Numerical Pain Scale — -3.2 units on a scale
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
Metastatic Urothelial Carcinoma
Primary: Number of Participants With Overall Response — 9; 8 Participants
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1) — 17.5; 27.5…
Healthy
Primary: Amygdala Response to Stimuli in the Emotion Recognition Test — 0.835; -0.759; 0.619; 0.503 BOLD percent signal change